

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Figure 1




Figure 2




Figure 3






Figure 4

The Effect of LL2-Onc vs LL2-hPanc on
Daudi Lymphoma cells



Figures



B




Figure 6




Figure 7

MIF⁺ Daudi/i.v. in SCID mice, 120996






Figure 8



Toxicity of LL2-Onc vs Onc or IT-dgRTA to Mice



Lethal Dose: Onc, 30mg/kg
& IT-dgRTA, 50 mg/kg

Drugs administered every 2 h
4x/day for 5 days. The arrows
indicate the days the mice with
each respective treatment were
found dead

RFB4-PE35KDEL, 1 x/day for 4 days: LD50 1 mg/kg
E. Mansfield et al., Bioconjugate Chem. 1996, 557